Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

United StatesUS aid freeze sows disruption in HIV, malaria product supply chains The U.S. government's foreign aid freeze has upended the supply chain for medical products crucial for fighting ...

Team Rocket has made their way to Pokemon Go, alongside their nefarious boss Giovanni. One of the toughest fights in the game, Giovanni is a real menace, and you’ll need to work hard if you ever ...